From: A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Pharmacokinetic parameter | Ridaforolimus | ||
---|---|---|---|
N | Mean‡ | 95% CI‡ | |
Day 1* | |||
Tlag (hr) | 15 | 2.00 | (0.97, 8.07) |
AUC0-24 (ng.hr/ml)† | 13 | 1846 | (1361, 2503) |
AUC0-∞ (ng.hr/ml) | 13 | 3648 | (3044, 4372) |
Cmax (ng/ml)† | 13 | 210 | (150, 295) |
C24hr (ng/ml)† | 15 | 34.8 | (26.0, 46.8) |
Tmax (hr) | 13 | 4.03 | (2.00, 7.97) |
Apparent t1/2 (hr) | 15 | 52.9 | (40.2, 65.6) |
Day 19** | |||
AUC0-24 (ng.hr/ml)† | 13 | 2014 | (1485, 2731) |
Cmax (ng/ml)† | 13 | 167 | (119, 234) |
C24hr (ng/ml)† | 13 | 49.7 | (36.4, 67.7) |
Tmax (hr) | 13 | 4.00 | (0.00, 6.00) |